J. Andrew Jones

Dr. J. Andrew Jones

Chemical, Paper, and Biomedical Engineering, Miami University, Oxford, OH, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones
XWXin Wang
Xin Wang

13 April 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BCBrady F. Cress
Brady F. Cress
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones
DKDaniel C. Kim
Daniel C. Kim
QLQuentin D. Leitz
Quentin D. Leitz
JEJacob A. Englaender
Jacob A. Englaender
Mattheos KoffasMattheos Koffas
Mattheos Koffas
Robust gene circuit construction requires use of promoters exhibiting low crosstalk. Orthogonal promoters have been engineered utilizing an assortment of natural and synthetic transcription factors, but design of large orthogonal promoter-repressor sets is complicated, labor-intensive, and often results in unanticipated crosstalk. The specificity and ease of targeting the RNA-guided DNA-binding protein dCas9 to any 20 bp user-defined DNA sequence makes it a promising candidate for orthogonal promoter regulation. Here, we rapidly construct orthogonal variants of the classic T7-lac promoter using site-directed mutagenesis, generating a panel of inducible hybrid promoters regulated by both LacI and dCas9. Remarkably, orthogonality is mediated by only two to three nucleotide mismatches in a narrow window of the RNA:DNA hybrid, neighboring the protospacer adjacent motif. We demonstrate that, contrary to many reports, one PAM-proximal mismatch is insufficient to abolish dCas9-mediated repression, and we show for the first time that mismatch tolerance is a function of target copy number. Finally, these promoters were incorporated into the branched violacein biosynthetic pathway as dCas9-dependent switches capable of throttling and selectively redirecting carbon flux in Escherichia coli. We anticipate this strategy is relevant for any promoter and will be adopted for many applications at the interface of synthetic biology and metabolic engineering.

1 December 2019 in Metabolic Engineering
Verified
Journal Article
Closed access
AAAlexandra M. Adams
Alexandra M. Adams
NKNicholas A. Kaplan
Nicholas A. Kaplan
ZWZhangyue Wei
Zhangyue Wei
JBJohn D. Brinton
John D. Brinton
CMChantal S. Monnier
Chantal S. Monnier
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones

20 June 2023 in Biotechnology and Bioengineering
Verified
Journal Article
Open access
JFJessica E. Flower
Jessica E. Flower
WGWilliam J. Gibbons
William J. Gibbons
AAAlexandra M. Adams
Alexandra M. Adams
XWXin Wang
Xin Wang
CBCaroline N. Broude
Caroline N. Broude
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones
Traditional psychedelics are undergoing a transformation from recreational drugs, to promising pharmaceutical drug candidates with the potential to provide an alternative treatment option for individuals struggling with mental illness. Sustainable and economic production methods are thus needed to facilitate enhanced study of these drug candidates to support future clinical efforts. Here, we expand upon current bacterial psilocybin biosynthesis by incorporating the cytochrome P450 monooxygenase, PsiH, to enable the de novo production of psilocybin as well as the biosynthesis of 13 psilocybin derivatives. The substrate promiscuity of the psilocybin biosynthesis pathway was comprehensively probed by using a library of 49 single‐substituted indole derivatives, providing biophysical insights to this understudied metabolic pathway and opening the door to the in vivo biological synthesis of a library of previously unstudied pharmaceutical drug candidates.

12 March 2022 in Metabolic Engineering Communications
Verified
Journal Article
Open access
AAAlexandra M. Adams
Alexandra M. Adams
NANicholas A. Anas
Nicholas A. Anas
ASAbhishek Kumar Sen
Abhishek Kumar Sen
JHJordan D. Hinegardner-Hendricks
Jordan D. Hinegardner-Hendricks
POPhilip J. O’dEll
Philip J. O’dEll
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones
Interest in the potential therapeutic efficacy of psilocybin and other psychedelic compounds has escalated significantly in recent years. To date, little is known regarding the biological activity of the psilocybin pathway intermediate, norbaeocystin, due to limitations around sourcing the phosphorylated tryptamine metabolite for in vivo testing. To address this limitation, we first developed a novel E. coli platform for the rapid and scalable production of gram-scale amounts of norbaeocystin. Through this process we compare the genetic and fermentation optimization strategies to that of a similarly constructed and previously reported psilocybin producing strain, uncovering the need for reoptimization and balancing upon even minor genetic modifications to the production host. We then perform in vivo measurements of head twitch response to both biosynthesized psilocybin and norbaeocystin using both a cell broth and water vehicle in Long-Evans rats. The data show a dose response to psilocybin while norbaeocystin does not elicit any pharmacological response, suggesting that norbaeocystin and its metabolites may not have a strong affinity for the serotonin 2A receptor. The findings presented here provide a mechanism to source norbaeocystin for future studies to evaluate its disease efficacy in animal models, both individually and in combination with psilocybin, and support the safety of cell broth as a drug delivery vehicle.

23 May 2023 in Metabolic Engineering
Verified
Journal Article
Closed access
LFLucas M. Friedberg
Lucas M. Friedberg
ASAbhishek Kumar Sen
Abhishek Kumar Sen
QNQuynh Nguyen
Quynh Nguyen
GTGabriel P. Tonucci
Gabriel P. Tonucci
EHElle B. Hellwarth
Elle B. Hellwarth
J. Andrew JonesJ. Andrew Jones
J. Andrew Jones